Article ID Journal Published Year Pages File Type
3865347 The Journal of Urology 2011 5 Pages PDF
Abstract
Sipuleucel-T therapy in patients with prostate cancer has a side effect profile that is characterized by mild to moderate, short-term, reversible adverse events. There was no evidence of a treatment related increase in autoimmune complications or secondary malignancies after treatment with sipuleucel-T. Sipuleucel-T can be administered safely in the outpatient setting.
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Authors
, , , , , , ,